Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leiomyosarcoma is a kind of cancer. It is aggressive & rare in nature. It affects supportive or connective human tissues. These tissues are cartilage, bones, muscles, fat, and blood muscles. Leiomyosarcoma is also known as LMS. Quite often, it is misinterpreted as leiomyoma. However, the latter is different. LMS actually constitutes five to ten percent of soft tissue cancers. Its wide prevalence drives the leiomyosarcoma market. Leiomyosarcoma is very unpredictable. It could be latent for a long time and appear after many years. The cancer is resistant and generally does not respond to radiation therapeutics or chemo-treatments. Normally, patients recover only if the sarcoma or tumor is operated on successfully, alongside wide margins early, though small & stationary in situ. Factors actually responsible for leiomyosarcoma remain unidentified. However, according to researchers, ecological & hereditary dangers are connected with the illness. Some hereditary conditions within families may potentially boost people’s chances of having the cancer. Yet, a direct connection is not seen. Majority of these patients expect lots of love, care, & support from their families and oncologists. Oncologists are cancer specialists. They operate from various medical centers and are best equipped to handle such cases. Several local oncologists witness only one or more such incidences in their entire career. Majority of the sarcoma centers partner with local doctors to help their patients. When patients are diagnosed with the illness, the latter’s stage is determined and necessary actions are taken. This is the key to their survival, with one treatment to another for different stages. The leiomyosarcoma market, with regards to therapeutic products, offers targeted drugs. These medicines are not conventional cytotoxic, but targeted to prevent cancerous cells from growing inside the body. Normally, these have mild side effects and are well-tolerated by patients. Some of the indications of leiomysarcoma are abdominal pain, jaundice, enlarged liver, abdominal uneasiness, renal vein obstruction, kidney dysfunction, and leg swelling. However, other illnesses may also display similar symptoms. Thus, patients are advised to consult their doctors for proper diagnosis and respective treatments. Surgery is the usually the first line of treatment for this cancer. Chemotherapy, radio-treatments, radiology therapeutics, immuno-therapeutics, and hormonal treatments are the other available alternatives.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Leiomyosarcoma Overview 6 Therapeutics Development 7 Pipeline Products for Leiomyosarcoma - Overview 7 Pipeline Products for Leiomyosarcoma - Comparative Analysis 8 Leiomyosarcoma - Therapeutics under Development by Companies 9 Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10 Leiomyosarcoma - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Leiomyosarcoma - Products under Development by Companies 14 Leiomyosarcoma - Products under Investigation by Universities/Institutes 15 Leiomyosarcoma - Companies Involved in Therapeutics Development 16 GlaxoSmithKline plc 16 Karyopharm Therapeutics, Inc. 17 Merck & Co., Inc. 18 Mirati Therapeutics Inc. 19 Novartis AG 20 Pharma Mar, S.A. 21 Leiomyosarcoma - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 everolimus - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 mocetinostat - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 NOV-110501 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 pazopanib hydrochloride - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 pembrolizumab - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 selinexor - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 trabectedin - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Leiomyosarcoma - Recent Pipeline Updates 60 Leiomyosarcoma - Dormant Projects 83 Leiomyosarcoma - Discontinued Products 84 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 86 Disclaimer 86
List of Tables Number of Products under Development for Leiomyosarcoma, H1 2015 7 Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Leiomyosarcoma - Pipeline by GlaxoSmithKline plc, H1 2015 16 Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 17 Leiomyosarcoma - Pipeline by Merck & Co., Inc., H1 2015 18 Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H1 2015 19 Leiomyosarcoma - Pipeline by Novartis AG, H1 2015 20 Leiomyosarcoma - Pipeline by Pharma Mar, S.A., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 30 Leiomyosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 60 Leiomyosarcoma - Dormant Projects, H1 2015 83 Leiomyosarcoma - Discontinued Products, H1 2015 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
